MRK Merck & Co., Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
03:15
Oct 08
Oct 08
3PRO TV
Merck preferred as a steadier biotech core
Park prefers Merck as a stable core position with reasonable momentum in a biotech allocation. He distinguishes it from faster-moving Moderna and Tempus ideas suitable for tactical swings, and presents Merck as his own steadier choice. This is an allocation recommendation, without a disclosed executed Merck purchase.
MRK
Merck & Co., Inc.
Long
—
—
03:15
Oct 08
Oct 08
3PRO TV
mRNA cancer vaccine plus Keytruda
mRNA cancer vaccine Phase 3 data in melanoma showed reduced recurrence, and combination with Merck's Keytruda provides a cash-cow partner; Moderna's platform and Merck's franchise expansion make the risk/reward attractive.
MRK
Merck & Co., Inc.
Long
1ST
—
—
02:25
Oct 08
Oct 08
3PRO TV
Merck LONG: Park’s preferred stable company with development momentum.
Park selects Merck when asked to choose one company from the AI-biotech development chain. She prefers its established revenue and relatively stable profile with additional development momentum, while treating more volatile diagnostics and design companies as swing candidates.
MRK
Merck & Co., Inc.
Long
1ST
—
—
About MRK Investor Commentary
Across the available history and selected sources, Buzzberg tracks MRK (Merck & Co., Inc.) across 45 sources: 52 bullish vs 0 bearish calls from 91 authors. Historical directional balance: 30% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 176 total trade ideas tracked. Past 7 days, before deduplication: 7 other directions. Latest voices: Park Hyun-ji, Kang Ha-na.